Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

MYGN SHAREHOLDER REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm

MYGN

Class-action law firm urges MYGN investors who have suffered losses of $50K+ to submit a loss form now to learn if they qualify to recover their investment losses.

SAN FRANCISCO, CA / ACCESSWIRE / Ocrober 10, 2019 / Hagens Berman reminds investors in Myriad Genetics, Inc. (NASDAQ: MYGN) of the pending securities class action and urges MYGN investors who have suffered losses in excess of $50,000 to contact the firm.

Class Period: Sept. 2, 2016 - Aug. 13, 2019

Lead Plaintiff Deadline: Nov. 26, 2019

Sign Up: www.hbsslaw.com/investor-fraud/MYGN

Contact An Attorney Now: MYGN@hbsslaw.com

(510) 725-3000

MYGN Securities Class Action:

According to the Complaint, Defendants misled investors about Myriad Genetics' GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients.

The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits. On August 13, 2019, Defendants disclosed that the FDA requested changes to GeneSight® and the Company had been in ongoing discussions with the FDA about the request. Defendants revealed that the FDA had specifically questioned the company as to whether the validity of GeneSight's purported benefits had been established.

This news drove the price of Myriad shares down $19.05, or down almost 43%, to close at $25.50 on August 14, 2019, erasing $1.4 billion in market capitalization.

"We're focused on investors' losses and whether Myriad misrepresented GeneSight®'s benefits," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email MYGN@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

SOURCE: Hagens Berman Sobol Shapiro LLP



View source version on accesswire.com:
https://www.accesswire.com/562776/MYGN-SHAREHOLDER-REMINDER-Hagens-Berman-Reminds-Myriad-Genetics-MYGN-Investors-of-Securities-Fraud-Lawsuit-Encourages-Investors-Who-Lost-50000-to-Contact-the-Firm





×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.